Vical (VICL), AnGes MG Ink Research Collaboration Deal; Takeover Rumors Around Innocoll (INNL)

vical_vicl

Vical Inc. (Nasdaq:VICL) shares soared over 15% in the extended session Tuesday after the company disclosed in a regulatory filing ( FORM 8-K ) with the Securities and Exchange Commission (SEC) a research collaboration deal with Japanese gene therapy company AnGes MG, Inc. (TYO:4563) to develop a program targeting chronic hepatitis B.

According to the SEC filing, AnGes will provide funding for the program, which research and preclinical development will be conducted by Vical. In return, AnGes will get an option to negotiate exclusive Japanese rights over the program.

VICL stock closed at $2.13, down $0.03 (or -1.39%) and 650,014 of its shares changed hands during the day.

a total volume of 650,014 shares traded.

Vical, which engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of life-threatening diseases, has 11.09M shares outstanding and VICL stock stock 52-week range is between $2.05 and $4.80 per share. At close on Tuesday, the company had a market capitalization of $23.63M

*

http://galaxystocks.com/wp-content/uploads/2017/03/Innocoll_Holdings_INNL.png

Shares of Innocoll Holdings plc (Nasdaq:INNL) climbed more than 50% in after-hours trading Tuesday, following a report from Reuters indicating that investment firm Gurnet Point Capital is in advanced talks to acquire the specialty pharmaceutical and medical device company – citing people familiar with the matter -.

3 weeks ago, Innocoll confirmed it was in discussions about the potential sale of its entire issued share capital, but the company didn’t mention the interested party to acquire it.

INNL stock finished the regular session in positive territory by 42.19% (or +$0.54) at $1.82 with a total volume of 7.03M shares traded, representing a large increase in activity versus its average volume (3m) of 1.26M shares.

Innocoll Holdings, which manufactures and sells collagen-based pharmaceutical products and devices, has 394.02M shares outstanding, market capitalization (intraday) of $504.34M and INNL stock one-year range is from $0.53 to $12.94 per share.

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/